Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Rhea-AI Summary
Predictive Oncology (NASDAQ: POAI) announced leadership and board additions on October 14, 2025 to support a new digital asset treasury strategy centered on the Aethir (ATH) token. The company named Shawn Matthews (CEO of DNA Holdings Venture and former CEO of Cantor Fitzgerald) to the board, appointed Thomas McLaughlin as Chief Investment Officer, and hired Sara Turken, JD as General Counsel. The hires link Predictive Oncology to DNA Holdings Venture (the PIPE investor) and add crypto asset management and life‑sciences legal expertise as the company pursues AI infrastructure accessibility via the Aethir ecosystem.
Positive
- Board adds Shawn Matthews on Oct 14, 2025
- Appointed Thomas McLaughlin as Chief Investment Officer
- Hired Sara Turken as General Counsel
- New treasury strategy targets Aethir (ATH) token to support AI infrastructure access
Negative
- Concentrated treasury focus on a single digital asset (ATH token) may increase exposure to crypto volatility
Insights
Predictive Oncology names crypto-focused leaders and a board addition to support a new Aethir (ATH) token treasury strategy.
The company appointed Shawn Matthews to the Board, Thomas McLaughlin as Chief Investment Officer, and Sara Turken, JD as General Counsel to back a digital asset treasury centered on the Aethir (ATH) token. These hires align operational roles (investment, legal, and board oversight) with a stated shift toward holding or leveraging a digital asset in corporate treasury.
Key dependencies and risks include operational execution, custody and compliance frameworks, and investor governance given DNA Holdings Venture, Inc. is named as the asset manager and a PIPE investor. The company’s move ties its treasury policy to a specific token, so future disclosures about holdings, custody arrangements, and any formal valuation or accounting treatment will determine material impact.
Monitorable items in the near term include public disclosures of treasury holdings, formal documentation of the asset manager relationship, and any filings that describe the scope of the digital asset strategy; these items will clarify financial exposure and governance within
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors
Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today announced additions to its leadership team and Board of Directors in support of the Company’s new digital asset treasury strategy focused on the Aethir (ATH) token.
The Company announced today that Shawn Matthews, CEO of DNA Holdings Venture, Inc., (the PIPE investor) and former CEO of investment bank Cantor Fitzgerald, has joined its Board of Directors; Thomas McLaughlin, CIO of DNA Holdings Venture, Inc., has joined the leadership team as Chief Investment Officer; and biopharmaceutical veteran Sara Turken, JD, has joined as the Company’s new General Counsel.
“On behalf of the Board and executive team, I would like to welcome Shawn, Thomas and Sara to Predictive Oncology as we embark on this exciting new path by leveraging our AI-driven drug discovery capabilities,” stated Raymond Vennare, Chairman and Chief Executive Officer of Predictive Oncology. “This innovative digital treasury asset strategy potentially addresses our own AI requirements while also allowing us to benefit from the ever-growing need for global AI infrastructure globally. Shawn, Thomas and Sara’s backgrounds align perfectly with our current needs and position us for long-term success. I look forward to their contributions.”
Mr. Shawn Matthews is the Chief Executive Officer of DNA Holdings Venture, Inc., Predictive Oncology’s asset manager, and founder and Chief Investment Officer of Hondius Capital Management, a global asset management firm he established in 2019. From 2009 to 2018, Mr. Matthews served as Chief Executive Officer and President of Cantor Fitzgerald & Co., where he oversaw more than 100 affiliated entities across a broad spectrum of financial services and fintech businesses. Mr. Matthews joined Cantor Fitzgerald in 2005 and held several senior roles, including Head of Capital Markets and Head of Mortgage Trading. Earlier in his career, Mr. Matthews held positions at Wertheim Schroder & Co., West Side Capital, and Alchemist Capital Management. Mr. Matthews holds a B.S. in Finance from Fairfield University and an MBA from Hofstra University.
Thomas McLaughlin also serves as Chief Investment Officer of DNA Asset Management and is one of the industry’s foremost leaders in liquid crypto markets. He has extensive experience trading and investing in digital assets since 2016 and is responsible for managing several different investment strategies focused on delivering the highest performance and execution in the crypto markets. Prior to joining DNA, Mr. McLaughlin was a founder and the Chief Investment Officer of Coral Capital, a multi-strategy crypto asset management firm with
Sara Turken is an accomplished legal executive with extensive experience in the life sciences and biotechnology sector. Ms. Turken brings deep expertise in corporate law, healthcare regulation and strategic transactions to biotechnology companies. Her background spans several public and private life sciences companies, including leading the legal functions at Excision BioTherapeutics and Rocket Pharmaceuticals. She also held positions of increasing responsibility at AgNovos Healthcare and Stryker Corporation. Ms. Turken began her legal career as a corporate associate at Covington & Burling LLP, focusing on securities and corporate transactions. Prior to that, she worked as an investment banking associate at Credit Suisse in the Industrials & Services Group. Ms. Turken also serves on the Board of Directors of Dorot, a non-profit focused on ending social isolation for older adults. She earned her JD, cum laude, from Harvard Law School and her BS from Cornell University.
About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with
Predictive Oncology also operates a digital asset treasury focused on the Aethir (ATH) token, creating the world’s first Strategic Compute Reserve. Through its holdings of ATH, the Company functions as an operator on the Aethir ecosystem, strengthening Aethir’s ability to provide the global infrastructure layer for the future of AI, democratizing access to AI infrastructure.
Predictive Oncology is headquartered in Pittsburgh, PA.
Investor Relations Contact:
Mike Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company’s current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as “believes,” “expects,” “endeavors,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “should” and “objective” and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that the proposed private placements and the transactions described herein may not be completed in a timely manner or at all, the failure to realize the anticipated benefits of the private placement and related transactions, including the Company’s proposed digital asset treasury strategy, economic conditions, fluctuations in the market price of ATH and other digital assets, the impact on the Company’s business of the evolving regulatory environment, the ability of the Company to execute on its digital asset treasury strategy and implications for shareholders and for the Company’s core business, the ability of the Aethir ecosystem to perform in a manner consistent with projections, receipt of shareholder approval for the exercise of the pre-funded warrants issued in connection with the Crypto PIPE and related matters, market and other conditions, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertake no duty to update such information except as required under applicable law.
FAQ
What did Predictive Oncology (POAI) announce on October 14, 2025?
Who is Shawn Matthews and what role did he take at POAI (NASDAQ: POAI)?
What experience does Thomas McLaughlin bring as POAI's new Chief Investment Officer?
Why did Predictive Oncology appoint Sara Turken as General Counsel for POAI?
How does POAI's new digital treasury strategy relate to its AI business?
